Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for…
Read moreNews & Views
Telix AGM – Chairman and CEO Addresses
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…
Read more
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement…
Read more
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing…
Read more
Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product
Telix has submitted a marketing authorisation application (MAA) in Europe for…
Read more
Seneffe Manufacturing Facility – Shareholder Walkthrough
Telix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing…
Read more
Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry…
Read more
Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call
Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with…
Read more
Activity Report and Sales Note to Accompany Appendix 4C
Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging…
Read more
AGM Notice of Meeting – Telix Pharmaceuticals Limited
Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May…
Read more